Armed with $270M in capital, Scorpion Therapeutics aims to broaden the reach of precision oncology

Armed with $270M in capital, Scorpion Therapeutics aims to broaden the reach of precision oncology

Source: 
MedCity News
snippet: 

Founded in 2020, Scorpion is agnostic about the potential therapies and targets it will explore with what it describes as its drug-hunting engine. But the company is hoping to unveil its first drug candidate this year.